secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evommune, Inc. (EVMN)
CIK:        0002044725
Form:       8-K
Filed at:   2026-11-04T22:10:44+00:00
Accession:  0001193125-26-447608
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Evommune in-licenses Hinova's VAV1 degrader EVO570 for $20M cash, $10M warrants, up to $1.1B milestones
--------------------------------------------------------------------------------

- Evommune pays Hinova $20M cash plus pre-funded warrants for 1,262,413 shares ($10M) at $0.001 exercise, for $30M total upfront.
- Milestones up to ~$1.1B: $150M development/regulatory and $920M commercial, plus tiered royalties from mid-single-digit to low-double-digit on ex-Greater China net sales.
- Rights cover worldwide excluding Greater China, which Hinova retains; Phase 1 expected to begin imminently, with a Phase 2 rheumatoid arthritis trial planned for 2027.
- $30M private placement: 4,966,889 shares at $6.04 to investors including Adage, Balyasny, OrbiMed and Squadron; closing expected on or about November 6, 2026.
- Pro forma cash, cash equivalents and investments estimated at ~$292.3M after closing, sufficient to fund operations into the second half of 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/0001193125-26-447608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-20261104.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-447608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer